Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: Results from 4 UK centres

SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status

“…Although concurrent chemo-radiation is now the international standard of care for patients with 55 Gy in 20 fractions over 4 weeks is a standard UK radical radiotherapy schedule, and is well tolerated in spite of the larger dose/fraction; a series of 600 patients reported equivalent outcomes to conventionally fractionated radiotherapy [11]. SOCCAR is the first randomised trial to prospectively evaluate this radiotherapy schedule with standard (80 mg/m 2 ) dose cisplatinum and vinorelbine (25 mg/m 2 ; 15 mg/m 2 during radiotherapy), as both sequential and concurrent treatment.…”

How to integrate stereotactic body radiation therapy and hypofractionation in the management of stage III lung cancer in the age of immunotherapy

“…most numerous study included 609 patients, from which 72% did not receive CT and the rest was treated with sequential CT. Eighty-three per cent of the treated patients had stage III NSCLC, and in this group of patients, the median survival was 20 months with 40% OS at twoyear. No grade 3 or 4 toxicities were detected, implying good tolerance 23 . In 2014, the results of the SOCCAR study were published in which the same RT scheme of 55 Gy in four weeks was used, comparing the sequential CT treatment against the concurrent CT.…”

Modelling the effects of lung cancer motion due to respiration

“…The 3DCRT plans were realized clinically, while the IMRT plans were simulated for the needs of this study. Both plans were prepared for Clinac 2300C/D (Varian Medical Systems, Palo Alto, CA, USA) and calculated using 6 MV photons delivered in 2 Gy fraction dose to the cumulative dose of 64 Gy [12,18,19] with gantry angles and collimator rotations adopted individually (based on patients' anatomy) to obtain optimal sparing of OARs and PTV coverage. The linear accelerator used in the study (Clinac 2300C/D) was equipped with Millennium 120 MLC.…”